

PRESS NEWS

Laura Chirica appointed new Board Director in Gradientech

Uppsala, 6 September 2021. The Extra General Meeting at the diagnostic company Gradientech today elected Laura Chirica new Board Director. Laura has 20 years of experience from leading positions within life science, bio process and diagnostic companies, and is currently Chief Commercial Officer at Immunovia AB.

"Laura Chirica has played a key role in the commercialization of Immunovia's first product, being part of the company's journey from the beginning until reaching market. During these years, Immunovia was approved for trading in 2015 on Nasdaq First North in Stockholm followed by Nasdaq Stockholm main market in 2018", says Sara Thorslund, CEO and co-founder of Gradientech. "All these experiences will be very valuable for Gradientech, especially now in the listing on Nasdaq First North which will be accomplished already in the second half of October 2021".

"I am looking forward to become part of the Gradientech Board of Directors to share the experiences I gained by creating and implementing successful commercialization strategies in the US, Europe and Asia during the last 20 years. Gradientech is an exciting company addressing the global health care problems of sepsis and the increasing antibiotic resistance. Gradientech's first product, QuickMIC, has the potential to make a true difference for the treatment of patients with sepsis", says Laura Chirica.

In addition, the Board of Directors in Gradientech consist of the members Gisela Sitbon (Chairman), Rolf Ehrnström, Ted Elvhage, Henrik Didner and Simon Turner and deputy Allan Asp.

For further information please contact:

Sara Thorslund, PhD, CEO Gradientech

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

About Gradientech

Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance.

www.gradientech.se